Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic LeukemiaMatthew S. Davids, John F. Seymour, John F. Gerecitano et al.|Clinical Cancer Research|2018Cited by 161
Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib.Jeffrey A. Jones, Steven Coutré, William G. Wierda et al.|Journal of Clinical Oncology|2016Cited by 22
Safety, efficacy and immune effects of venetoclax 400 mg daily in patients with relapsed chronic lymphocytic leukemia (CLL).Matthew S. Davids, William G. Wierda, Andrew W. Roberts et al.|Journal of Clinical Oncology|2016Cited by 13